Seeking Alpha·3d ago
Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call TranscriptCaris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
Caris Life Sciences has grown revenue to $275.4M in 2026Q3, a 27.0% year-over-year rise, with gross margins holding near 66.2%, which suggests the diagnostics platform retains pricing power.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue rose to $275.4M in 2026Q3 with gross margin of 66.2%, but operating margin compressed to 7.0% as SG&A climbed to $129.1M, leaving operating income of only $19.3M despite strong top-line expansion.
Caris Life Sciences reported a 97% year-over-year revenue increase, with Q4 revenue reaching US$292.9 million and trailing 12-month revenue at US$812.0 million.
Expectations for earnings to grow about 70.5% per year, with profitability projected within three years, alongside a basic EPS of US$0.29 in Q4.
The company leverages a proprietary genomic database, providing a competitive edge in diagnostics and anatomic pathology services.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.05+77.7% vs $0.03 | $275M+7.8% vs $255M |
Q3 2026 Aug 5, 2026 | -$0.00-139.2% vs $0.01 | $264M+10.8% vs $238M |
Q2 2026 May 7, 2026 | -$0.00+91.0% vs -$0.02 | $216M+3.2% vs $209M |
Q1 2026 Feb 26, 2026 | $0.28+2700.0% vs $0.01 | $293M+39.8% vs $210M |
Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
Caris Life Sciences NASDAQ: CAI raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company also reported lower quarterly profit as it increased spending on its sales force, marketing and new tests.
Caris Life Sciences,?Inc. (CAI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.08 per share a year ago.
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period.
Benchmark CAI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Caris Life Sciences, Inc. (CAI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.23 | $7.13B | 77.51 | 96.97% | 9.16% | 16% | — | |
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $150.87 | $20.01B | -41.81 | 32.88% | -37.93% | — | — | |
| $12.25 | $640.38M | -4.80 | — | -194.74% | -41.33% | — | |
| $78.56 | $4.06B | 33.58 | 13.79% | 25.86% | 34.08% | — |
Caris Life Sciences, Inc. (CAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Caris Life Sciences, Inc. (CAI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Aug 5, 2026·SEC
Jun 5, 2026·SEC
Get notified when CAI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Caris Life Sciences, Inc. (CAI) stock FAQ — growth, dividends, profitability & financials explained
Caris Life Sciences, Inc. (CAI) reported $1.05B in revenue over the trailing twelve months. Revenue was $812.0M in fiscal year 2025. That is 1589% more than the $48.1M of fiscal year 2003.
Caris Life Sciences, Inc. (CAI) grew revenue by 61.5% over the trailing twelve months, compared with the twelve months before.
Yes. Caris Life Sciences, Inc. (CAI) earned $96.1M in net income over the trailing twelve months (a 9.2% net margin).
Caris Life Sciences, Inc. (CAI) had a return on equity (ROE) of 16.0% over the trailing twelve months. That is above the market's typical 10-15%.
Caris Life Sciences, Inc. (CAI) generated $51.4M in free cash flow over the trailing twelve months.
